A Contract Research and
                  Development Company
Chemistry Banner

Grants

Organix was awarded a Fast Track SBIR grant to design compounds to inhibit breast cancer metastasis . Dr. Anu Mahadevan is the Principal Investigator on this two year SBIR grant R44CA206723 entitled "Targeting breast cancer metastasis with Id1" awarded by National Cancer Institute (NCI). Organix is collaborating with scientists at CPMC Research Institute in this program.

Organix was awarded an SBIR grant to design compounds to inhibit breast cancer metastasis by suppressing Id-1 expression. Dr. Anu Mahadevan is the Principal Investigator on this one-year expanded SBIR grant R43CA171415 entitled "Targeting breast cancer metastasis with inhibitors of Id-1" awarded by National Cancer Institute (NCI). Organix is collaborating with scientists at CPMC Research Institute in this program.

Organix was awarded an SBIR grant to design compounds which show selective and potent CB2 agonist activity with pain suppression potential. Dr. Anu Mahadevan is the Principal Investigator on this one-year expanded SBIR grant R43DA036289 entitled "Cannabinoid Receptor Agonists for Treatment of Chronic Pain" awarded by National Institute on Drug Abuse (NIDA). Organix is collaborating with scientists at Virginia Commonwealth University in this program.

Organix was awarded an SBIR Grant to design radioligands as molecular tools to explore the interaction of methamphetamine with its biological target, the vesicular monoamine transporter. Dr. Peter Meltzer is the Principal Investigator on this SBIR Grant R43DA035006 entitled "The first reversible radioligand for the VMAT2 [3H]reserpine binding site" awarded by the National Institute on Drug Abuse. There are currently no medications available to address the problem of methamphetamine addiction and the tools developed under this grant will accelerate the search for medications for methamphetamine addiction. Organix is collaborating with scientists at Veterans Administration Research Foundation in Portland Oregon in this program.

Dr. Howard Sard is the Principal Investigator on a two-year grant R43MH095315 “Benzodiazepine Analogs as Novel Treatments for Catatonia” awarded by the National Institute of Mental Health. The goal of this program is to synthesize and evaluate novel benzodiazepine derivatives as potential treatments for catatonia. Organix is collaborating with scientists at the University of North Carolina in these studies.

Grants

Dr. Anu Mahadevan is the Principal Investigator on a two-year grant RO3DA026593 “Development of CB2 Agonists for Treatment of Pain” and two five year grants RO1DA005488 “Synthesis of Δ9-Tetrahydrocannabinol Related Compounds” and P01-DA-009789 “Endogenous Cannabinoids and Brain Function” awarded by National Institute on Drug Abuse. The goal of these synthetic programs is elucidation of the role that receptors play in the complex pharmacological actions of cannabinoids, particularly pain, reward, cognition, and drug dependence. Organix is collaborating with scientists at Virginia Commonwealth University and Research Triangle Institute in these studies.

Dr. Peter Meltzer has received an award from Oregon Health & Science University to design and synthesize prospective inhibitors of the vesicular monoamine uptake mechanism, VMAT2. The goal of this grant is to discover potential medications for methamphetamine addiction. Organix is collaborating with scientists at OHSU in these studies.

Back to Top

Research at Organix